Benzinga · Aug 24, 2026
Maxim Group Downgrades NexGel to Hold
Maxim Group analyst Naz Rahman downgrades NexGel (NASDAQ:NXGL) from Buy to Hold.
NASDAQ · NXGL
Healthcare · Medical - Instruments & Supplies
$0.35
Up+$0.00 (+0.60%)
Updated Aug 31, 2026, 11:37 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NXGL closed at $0.35 after 20 trading sessions, down 16.82% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $0.341 | $0.3591 | $0.3338 | $0.352 | 196.12K |
| Aug 27, 2026 | $0.3453 | $0.37 | $0.3284 | $0.3499 | 331.26K |
| Aug 26, 2026 | $0.36 | $0.37 | $0.3401 | $0.356 | 237.52K |
| Aug 25, 2026 | $0.358 | $0.3911 | $0.3539 | $0.356 | 539.31K |
| Aug 24, 2026 | $0.3075 | $0.38 | $0.3001 | $0.38 | 25.01M |
| Aug 21, 2026 | $0.37 | $0.37 | $0.3292 | $0.33 | 350.66K |
| Aug 20, 2026 | $0.4038 | $0.4038 | $0.3782 | $0.3873 | 552.57K |
| Aug 19, 2026 | $0.381 | $0.417 | $0.37 | $0.4039 | 87.75K |
| Aug 18, 2026 | $0.355 | $0.4092 | $0.355 | $0.3845 | 179.82K |
| Aug 17, 2026 | $0.44 | $0.4469 | $0.3003 | $0.3755 | 1.85M |
| Aug 14, 2026 | $0.539 | $0.59 | $0.49 | $0.565 | 1.65M |
| Aug 13, 2026 | $0.4002 | $0.536 | $0.40 | $0.4887 | 1.64M |
| Aug 12, 2026 | $0.403 | $0.42 | $0.395 | $0.4109 | 151.05K |
| Aug 11, 2026 | $0.3662 | $0.475 | $0.3661 | $0.426 | 1.59M |
| Aug 10, 2026 | $0.38 | $0.3822 | $0.3607 | $0.3624 | 78.58K |
| Aug 7, 2026 | $0.3408 | $0.40 | $0.3408 | $0.38 | 171.74K |
| Aug 6, 2026 | $0.4052 | $0.4052 | $0.3303 | $0.339 | 385.05K |
| Aug 5, 2026 | $0.4168 | $0.4578 | $0.3968 | $0.411 | 56.04K |
| Aug 4, 2026 | $0.436 | $0.4492 | $0.415 | $0.421 | 30.59K |
| Aug 3, 2026 | $0.4343 | $0.4343 | $0.421 | $0.4232 | 15.8K |
The latest Smart Investors Daily articles mentioning NXGL.
NXGL research
Company profile and research snapshot.
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Maxim Group | Hold | — |
| Mar 12, 2026 | Maxim Group | Buy | — |
| Feb 25, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Maxim Group analyst Naz Rahman downgrades NexGel (NASDAQ:NXGL) from Buy to Hold.
Benzinga · Aug 20, 2026
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve
Benzinga · Aug 17, 2026
US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech shares up 0.4%, consumer staples down 0.8%.
Benzinga · Aug 17, 2026
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.12) by 233.33 percent. This is a 344.44 percent decrease over losses of $(0.09) per share from the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning NXGL.